In a report released today, Judah Frommer from Morgan Stanley maintained a Hold rating on Galapagos (GLPG – Research Report), with a price ...

Galapagos NV. announced its plans to split into two listed entities by mid-2025 by spinning off its activities focused on ...

Galapagos NV (GLPG) has been beaten down lately with too much selling pressure. While the stock has lost 14.4% over the past four weeks, there is light at the end of the tunnel as it is now in ...

Galapagos NV (NASDAQ:GLPG – Get Free Report) has received an average recommendation of “Reduce” from the eight research firms ...

Fintel reports that on January 23, 2025, Barclays downgraded their outlook for Galapagos NV - Depositary Receipt () (NasdaqGS:GLPG) from Equal-Weight to Underweight. Analyst Price Forecast Suggests 48 ...

Barclays downgraded Galapagos (GLPG) to Underweight from Equal Weight with a price target of EUR 22, down from EUR 30. With Galapagos’ ongoing ...

Mechelen, Belgium; June 14, 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present encouraging new data from the ongoing Phase 1/2 ATALANTA-1 study of CD19 ...

Specifically, Catalent's commercial cell therapy manufacturing facility in Princeton, New Jersey, will support manufacturing ...

Catalent, Inc., a leader in enabling the development and supply of better treatments for patients worldwide, today announced a strategic collaboration with Galapagos NV (Euronext & NASDAQ: GLPG), a ...

The GLPG support staff will personally match you with a best-fit therapist who accepts your insurance and is available to see you online or in person at a time that works for you. The GLPG ...

Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...